Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041).
Choi MC, Kim YM, Lee JW, Lee YJ, Suh DH, Lee SJ, Lee TS, Lee M, Park DC, Kim MK, Lee JM, Shim SH, Jeon S, Min KJ, Kim MK, Kim BW, Park JY, Kim BG, Kim DY, Kim MH, Kim HS, Lee JY. Choi MC, et al. Cancers (Basel). 2020 Oct 29;12(11):3188. doi: 10.3390/cancers12113188. Cancers (Basel). 2020. PMID: 33138190 Free PMC article.
This study investigated the antitumor activity and safety of pembrolizumab in patients with recurrent cervical cancer in real-world practice. We conducted a multi-center retrospective study of …
This study investigated the antitumor activity and safety of pembrolizumab in patients with recurrent cervica
Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
Alholm Z, Monk BJ, Ting J, Pulgar S, Boyd M, Sudharshan L, Bains S, Nicacio L, Coleman RL. Alholm Z, et al. Gynecol Oncol. 2021 May;161(2):422-428. doi: 10.1016/j.ygyno.2021.03.002. Epub 2021 Mar 17. Gynecol Oncol. 2021. PMID: 33741208
This study characterizes the patient experience, treatment patterns, and clinical outcomes of patients who initiated second-line (2L) therapy for r/mCC in a US community oncology setting. METHODS: This is an observational study of cervical
This study characterizes the patient experience, treatment patterns, and clinical outcomes of patients who initi …